Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion

DUBLIN, May 9, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its first quarter 2017 continuing operations performance. First Quarter 2017 Continuing Operations (unaudited; $ in millions, except per share amounts) Q1 '17 Q1 '16 Q4 '16 Q1 '17 v Q1 '16 Q1 '17 v Q4 '16 Total net revenues** $ 3,572.9 $ 3,399.3 $ 3,864.3 5.1% (7.5)% Operating (Loss) $ (906.0) $ (171.5) $ (900.0) 428.3% 0.7% Diluted EPS - Continuing Operations $ (7.85) $ (0.41) $ (0.31) n.m. n.m. SG&A Expense $ 1,185.2 $ 1,096.3 $ 1,276.8 8.1% (7.2)% R&D Expense $ 759.9 $ 403.1 $ 913.3 88.5% (16.8)% Continuing Operations Tax Rate 17.2% 81.6% 96.4% (64.4)% (79.2)% Non-GAAP Adjusted Operating Income $ 1,617.8 $ 1,733.9...